Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Ciphergen Biosystems(CIPH): -- Ignore unavailable to you. Want to Upgrade?

To: nigel bates who wrote (180)	12/20/2003 5:01:04 PM
From: tuck	Read Replies (1) \| Respond to of 510

>>Expert Opin Biol Ther. 2004 Jan;4(1):83-93. Use of proteomic analysis to monitor responses to biological therapies. Espina V, Dettloff KA, Cowherd S, Petricoin EF 3RD EF, Liotta LA. National Cancer Institute, Building 10, Room B1B53, 9000 Rockville Pike, Bethesda, MD 20892, USA. espinav@mail.nih.gov Proteomics has the potential to revolutionise diagnosis and disease management. Serum protein pattern profiling by surface-enhanced laser desorption/ionisation time of flight (SELDI-TOF) mass spectrometry is emerging as a novel approach to discover protein patterns capable of distinguishing disease and disease-free states with high sensitivity and specificity. This method has shown great promise for early diagnosis of ovarian cancer and is being applied to a range of pathological states. Protein microarray technology is being evaluated as a new means to track biological responses to therapy. Through the measurement of key protein phosphorylation sites at different stages of disease progression or before and after treatment, protein signal pathways can be mapped and thus become the starting point for individualised therapy. Laser capture microdissection (LCM) coupled with immunostaining of protein microarrays allows isolation of pure cell populations and relative quantitation of phosphorylated and non-phosphorylated forms of the cell's key signalling proteins. This technology is currently in use at the National Institutes of Health in Phase II clinical trials of metastatic breast and ovarian cancer. Cell survival and apoptotic protein pathways are monitored as biological markers of disease progression in these clinical trials. Proteomic technologies, such as serum protein pattern profiling, combined with protein microarray technologies, constitute a new paradigm for detecting disease and monitoring disease response to therapy. Ultimately, proteomics and genomics will become integrated into cancer patient management through the design and tracking of individualised therapy.<< Annoyingly enough, the actual microarrays being used in this trial appear to be developed in the CCR Laboratory of Pathology (of which Liotta is the head), Clinical Proteomics Section. I can't find any info on it, because the LP search engine seems to be having an off day -- it can't find anything right now. Here's the protocol of the trial: clinicaltrials.gov Since this started in 1999, about when Ciphergen's systems were launched, it is possible that future trials will use Ciphergen's proteinchips in this manner. That would be very nice, anyway. Cheers, Tuck